ML19134A118
| ML19134A118 | |
| Person / Time | |
|---|---|
| Site: | 11006301 |
| Issue date: | 05/10/2019 |
| From: | David Skeen NRC/OIP |
| To: | Rothwell P Vertex Pharmaceuticals Incorporated |
| Savoy J | |
| References | |
| Download: ML19134A118 (2) | |
Text
United States of America Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.
NRC LICENSE NO.: XMAT443 Page 1 of 2 NRC DOCKET NO.: 11006301 LICENSE EXPIRES: June 30, 2023 NRC FORM 250 (10-07)
Nuclear Regulatory Commission Washington, D.C. 20555 EXPORT LICENSE Vertex Pharmaceuticals Incorporated 50 Northern Ave Boston, MA 02210 LICENSEE ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)
INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)
OTHER U.S. PARTY(IES) TO EXPORT Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974.
This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of the NRC.
THIS LICENSE IS INVALID UNLESS SIGNED BELOW BY AUTHORIZED NRC REPRESENTATIVE NAME AND TITLE:
DATE OF ISSUANCE:
APPLICANT'S
REFERENCE:
Application dated 01/30/18 ULTIMATE DESTINATION(s): China David L. Skeen, Deputy Director Office of International Programs EXPORT LICENSE Attn: Paula Rothwell SIGNATURE:
QUANTITY(IES) 5,000 kilograms See following page(s)
None See following page(s)
DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)
Deuterium in the form of deuterium gas, deuterium oxide, and deuterium compounds.
CONDITION: A license amendment request is required for the addition of any intermediate consignees to this export license.
May 10, 2019 David L. Skeen Digitally signed by David L. Skeen Date: 2019.05.10 10:51:13 -04'00'
XMAT443 Page 2 of 2 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
1.
2.
3.
CARBOGEN AMCIS (Shanghai) Co., Ltd.
No. 69 Shungong Road Shanghai Chemical Industry Park Shanghai China (manufacture active pharmaceutical ingredients for non-nuclear end use in clinical trials for the treatment of cystic fibrosis)
Changzhou SynTheAll Pharmaceutical Co., Ltd.
589 North Yulong Road XinBei District Changzhou 213127 China (manufacture active pharmaceutical ingredients for non-nuclear end use in clinical trials for the treatment of cystic fibrosis)
Shanghai SynTheAll Pharmaceutical Co., Ltd.
9 Yuegong Road Jinshan District Shanghai 201507 China (manufacture active pharmaceutical ingredients for non-nuclear end use in clinical trials for the treatment of cystic fibrosis)
OTHER U.S. PARTY(IES) TO EXPORT:
1.
2.
3.
4.
Aldrich Chemical Co. LLC 6000 N. Teutonia Avenue Milwaukee, WI 53209 (supplier/distributor)
Aldrich Chemical Co. LLC 3858 Benner Road Miamisburg, OH 45342 (supplier/distributor)
Cambridge Isotope Laboratories, Inc.
50 Frontage Road Andover, MA 01810 (supplier/distributor)
Sigma Aldrich Fine Chemicals (SAFC) 5485 Country Road V Sheboygan Falls, WI 53085 (supplier/distributor)